Brucellosis. Brucellosis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 100 mg gabapentin tablets twice daily (200 mg daily). Intervention 2: Control group: 250 mg naproxen tablets twice daily (500 mg daily).
Sponsors
Shahroud University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of brucellosis There is no history of systemic disease (such as diabetes or thyroid disease), vascular diseases, coagulation problems (eg hemophilia), history of gastrointestinal bleeding and structural disorders (scoliosis and spondylolisthesis, etc.) No neurological symptoms such as SLR and Cross-SLR, decreased tendin reflexes and decreased sensation in examination Age range 15 to 65 years Complaint of severe and Fairly intense bone and joint pain Desire and satisfaction to enter the study
Exclusion criteria
Exclusion criteria: Corticosteroid injections in the lumbar region or other areas of the body within 3 months before and during the study Dissatisfaction to continue treatment Those who use drugs A history of back pain or repetitive back pain is more than 4 times a year Taking multiple medications for other illnesses (such as hypnotics, anti-leptic, relaxants) Severe hypersensitivity to any of the two drugs, gabapentin and naproxen Dissatisfaction with cooperation and participation in the project
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intensity of pain. Timepoint: On the third, fifth and seventh day after the intervention. Method of measurement: Visual Analog Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarnaz Rivjam
Shahroud University of Medical Sciences
Outcome results
None listed